Tin tức & Cập nhật

Chỉ hiển thị Multimedia
ALK+ NSCLC: Real-world patterns and outcomes of treatment after 1L brigatinib
ALK+ NSCLC: Real-world patterns and outcomes of treatment after 1L brigatinib
30 Apr 2024 bởiChristina Lau

Following first-line (1L) brigatinib treatment, most patients with ALK-positive (ALK+) non-small-cell lung cancer (NSCLC) received an ALK tyrosine kinase inhibitor (TKI) as second-line (2L) therapy and experienced prolonged clinical benefit, a retrospective chart review of patients enrolled in the phase III ALTA-1L trial has shown.

ALK+ NSCLC: Real-world patterns and outcomes of treatment after 1L brigatinib
30 Apr 2024
Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir–ritonavir
Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir–ritonavir
30 Apr 2024 bởiMike Ng

Treating COVID-19 patients who had been vaccinated or did not have risk factors for severe disease with ritonavir-boosted nirmatrelvir (nirmatrelvir–ritonavir) did not expedite the time to symptom alleviation, reported investigators in the EPIC-SR trial.

Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir–ritonavir
30 Apr 2024
Nutrient deficiency tied to sensory sensitivity in autism, intellectual disability
Nutrient deficiency tied to sensory sensitivity in autism, intellectual disability
29 Apr 2024

Children with autism spectrum disorder (ASD) enjoy better dietary intake but show worse sensory sensitivity than those with intellectual disability (ID), suggests a study.

Nutrient deficiency tied to sensory sensitivity in autism, intellectual disability
29 Apr 2024
Supplement cocktail boosts COVID-19 treatment arsenal
Supplement cocktail boosts COVID-19 treatment arsenal
29 Apr 2024